Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer
This article was originally published in The Pink Sheet Daily
FDA granted Opdivo an ultra-rapid approval for the treatment of classical Hodgkin lymphoma that has relapsed or progressed, making it the first PD-1 inhibitor approved for hematological cancer.
You may also be interested in...
Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
The latest drug development news and highlights from our FDA Performance Tracker.
Novartis is closing its high-profile cell and gene therapy unit – the one responsible for developing CAR-T therapies. The move suggests Novartis’s outlook for the CAR-T field may be changing, though it’s not clear why.
Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.